Deutsche Bank Maintains Buy Rating on Allergen (AGN)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall St slips on rising bond yields; Walmart results weigh
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
Allergan (AGN) Issues Statement on Valeant (VRX) Letter
October 27, 2014 9:12 AM EDTAllergan, Inc. (NYSE: AGN) today issued the following statement in response to Valeant Pharmaceuticals International (NYSE: VRX) October 27, 2014 letter to the Allergan Board of Directors.
Delivering value to Allergans stockholders remains the Boards highest priority. If Valeant were to make an increased offer, the Board would carefully consider it and respond in due course. However, to date, as we have noted repeatedly, Valeants... More
Allergan (AGN) Tops Q3 EPS by 10c; Issues Strong Q4, FY14 EPS Outlook
October 27, 2014 7:02 AM EDTAllergan (NYSE: AGN) reported Q3 EPS of $1.78, $0.10 better than the analyst estimate of $1.68. Revenue for the quarter came in at $1.79 billion versus the consensus estimate of $1.78 billion.
Allergan sees FY2014 EPS of $6.27-$6.30, versus the consensus of $6.12. Allergan sees FY2014 revenue of $7.08-7.155 billion,... More
